CheckMate 057: Nivolumab Superior to Docetaxel in Previously Treated Advanced Nonsquamous NSCLC

May 29-June 2, 2015; Chicago, Illinois
Results from the CheckMate 057 trial demonstrate superior OS and favorable safety profile with nivolumab vs docetaxel in patients with advanced nonsquamous NSCLC who failed prior platinum-based doublet chemotherapy.
Format: Microsoft PowerPoint (.ppt)
File Size: 657 KB
Released: May 31, 2015

Acknowledgements

Educational grant provided by:
AstraZeneca
Bayer HealthCare Pharmaceuticals Inc.
Bristol-Myers Squibb
Celgene Corporation
Genentech BioOncology
Incyte
Novartis Pharmaceuticals Corporation

Related Content

On-demand webcast from a live CCO webinar capturing global perspectives from Drs. Edward S. Kim and Luis Paz-Ares on the optimal management of patients with EGFR+ NSCLC

Edward S. Kim, MD, FACP, FASCO Luis Paz-Ares, MD, PhD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Registered Nurses: 1.0 Nursing contact hour Released: July 29, 2021 Expired: July 28, 2022

David Planchard, MD, PhD, discusses barriers to osimertinib access worldwide and future directions for the management of advanced EGFR-mutated NSCLC.

David Planchard, MD, PhD Released: July 29, 2021

On-demand webcast from CCO where clinical experts discuss how to optimally integrate the latest clinical data on predictive biomarkers to guide treatment decisions in advanced NSCLC

Suresh S. Ramalingam, MD, FACP, FASCO
Program Director
Stephen V. Liu, MD Lecia V. Sequist, MD, MPH
Physicians: maximum of 2.0 AMA PRA Category 1 Credits Released: July 26, 2021 Expired: July 25, 2022

Interactive algorithm tool with NCCN Guidelines® recommendations for Management of Immune Checkpoint Inhibitor–Related Toxicities v3.2021, from CCO

Released: July 22, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue